-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Abcam (NASDAQ:ABCM) Given New GBX 2,200 Price Target at Royal Bank of Canada
Abcam (NASDAQ:ABCM) Given New GBX 2,200 Price Target at Royal Bank of Canada
Abcam (NASDAQ:ABCM – Get Rating) had its price target lifted by Royal Bank of Canada from GBX 1,700 ($20.54) to GBX 2,200 ($26.58) in a research report released on Wednesday, The Fly reports.
Separately, Panmure Gordon upgraded shares of Abcam from a hold rating to a buy rating in a report on Monday, September 5th.
Get Abcam alerts:Abcam Price Performance
Shares of ABCM stock opened at $16.17 on Wednesday. The firm has a fifty day moving average of $14.85 and a 200-day moving average of $15.54. Abcam has a 12-month low of $12.54 and a 12-month high of $24.00.
Institutional Investors Weigh In On Abcam
Several large investors have recently made changes to their positions in the stock. Advisor Group Holdings Inc. increased its holdings in Abcam by 20.5% during the fourth quarter. Advisor Group Holdings Inc. now owns 5,876 shares of the company's stock worth $138,000 after buying an additional 999 shares during the last quarter. TD Asset Management Inc. lifted its stake in Abcam by 63.0% in the fourth quarter. TD Asset Management Inc. now owns 72,773 shares of the company's stock valued at $1,714,000 after acquiring an additional 28,130 shares during the last quarter. Bank of Montreal Can lifted its stake in Abcam by 0.9% in the fourth quarter. Bank of Montreal Can now owns 105,928 shares of the company's stock valued at $2,525,000 after acquiring an additional 956 shares during the last quarter. 2Xideas AG acquired a new stake in Abcam in the fourth quarter valued at $16,691,000. Finally, HM Payson & Co. acquired a new stake in Abcam in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 11.82% of the company's stock.About Abcam
(Get Rating)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Read More
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Four Cheap Stocks With Interesting Insider Activity
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.
Abcam (NASDAQ:ABCM – Get Rating) had its price target lifted by Royal Bank of Canada from GBX 1,700 ($20.54) to GBX 2,200 ($26.58) in a research report released on Wednesday, The Fly reports.
据The Fly报道，在周三发布的一份研究报告中，加拿大皇家银行将Abcam(纳斯达克：ABCM-GET评级)的目标价从1,700英镑(20.54美元)上调至2,200英镑(26.58美元)。
Separately, Panmure Gordon upgraded shares of Abcam from a hold rating to a buy rating in a report on Monday, September 5th.
另外，Panmure Gordon在9月5日星期一的一份报告中将Abcam的股票评级从持有评级上调为买入评级。
Abcam Price Performance
Abcam性价比
Shares of ABCM stock opened at $16.17 on Wednesday. The firm has a fifty day moving average of $14.85 and a 200-day moving average of $15.54. Abcam has a 12-month low of $12.54 and a 12-month high of $24.00.
周三，ABCM的股票开盘报16.17美元。该公司的50日移动均线切入位为14.85美元，200日移动均线切入位为15.54美元。Abcam的12个月低点为12.54美元，12个月高位为24.00美元。
Institutional Investors Weigh In On Abcam
机构投资者在Abcam上发表看法
About Abcam
关于abcam
(Get Rating)
(获取评级)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Abcam plc是一家生命科学公司，专注于识别、开发和分发用于科学研究、诊断和药物发现的试剂和工具。它的主要产品包括一抗和二抗；结合抗体和结合试剂盒；单链和多重免疫分析；包括细胞因子的蛋白质和多肽；编辑的细胞系和裂解产物；以及各种其他产品，包括细胞活动试剂盒、miRNA试剂盒、生物化学品和细胞信号途径工具。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Four Cheap Stocks With Interesting Insider Activity
- 免费获取关于abcam(ABCM)的StockNews.com研究报告
- 这家医疗设备制造商准备好继续反弹了吗？
- 第三季度财报公布前最值得关注的五(5)只股票
- Take-Two Interactive是否已经退化为一招小马？
- 健康饮料制造商Celsius能否超越其Monster竞争对手？
- 具有有趣内幕活动的四只廉价股票
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.
接收abcam日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Abcam和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧